This cohort study examines the rates of mild cognitive impairment and probable dementia among initiators of an angiotensin II receptor blocker (ARB) vs angiotensin-converting enzyme inhibitor (ACEI)–based antihypertensive medication regimen. Here, ACE is linked to Cognitive impairment.